Horizon Pharma (HZNP) Tops Q3 EPS by 30c; Boosts FY15 Revenue Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
Horizon Pharma plc Announces Exceptional Third-Quarter 2015 Financial Results and Significantly Raises Full-Year 2015 Sales and Adjusted EBITDA Guidance
November 6, 2015 7:00 AM ESTDUBLIN, IRELAND -- (Marketwired) -- 11/06/15 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, announced its third-quarter 2015 financial results today.
Quarterly Financial Highlights
(in millions except for per share amounts and % % percentages) Q3 15 Q3 14 Change 9M 15 9M 14 Change --------- --------- ------- --------- --------- ------- Net sales $ 226.5 $ 75.1 202 $ 512.5 $ 193.1 165 Net income (loss) 3.3 2.1 57 15.5 (232.0) NM Adjusted non-GAAP net income 117.0 19.4 503 203.4 46.2 340 Adjusted EBITDA 131.1 22.1 493 239.7 52.3 358 Earnings (loss) per share - basic $ 0.02 $ 0.03 -33 $ 0.11 $ (3.17) NM Adjusted non-GAAP earnings per share - basic 0.74 0.25 196 1.40 0.63 122 Earnings (loss)... More
